BPRL PRIVATE LIMITED | Herbal Division | Super speciality Division
Targeted therapy of Tyrosine-kinase inhibitor

Imatinib Mesylate

As monotherapy in

allogenic hematopoietic stem cell transplantation (allo-HSCT)-

Targeted to WIN in

In Chronic Myelogenous Leukemia (CML)

In First Line therapy compared with Interferon

In Monotherapy

Acute Lymphoblastic Leukemia (ALL)

In Gastrointestinal Stromal Tumor

Also Recommeded in

In Glioma

In Dermatofibrosarcoma protuberans